MedTrace Logo

First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC

NCT04408118 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-06-04

No results posted yet for this study

Summary

This is a multicenter, open-label, single-arm, phase II clinical trial to evaluate to evaluate the efficacy and safety of first line atezolizumab in combination with paclitaxel and bevacizumab (Avastin®) in patients with advanced or metastatic triple-negative breast cancer (mTNBC)

Conditions

Interventions

DRUG

Atezolizumab

Atezolizumab (840 mg) will be administered intravenously on Days 1 and 15. The first infusion of atezolizumab will be administered over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.

DRUG

Paclitaxel

Will be administered on days 1, 8 and 15 via IV infusion over 1 hour.

DRUG

Bevacizumab

Will be administered intravenously over 30-90 minutes on Days 1 and 15.

Sponsors & Collaborators

Principal Investigators

  • Antonio Llombart, PhD · MedSIR

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-05
Primary Completion
2023-12-07
Completion
2023-12-07

Countries

  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04408118 on ClinicalTrials.gov